Oncoprotein Myc is known to be dysregulated in about 70% of cancers, and it is highly expressed in leukemias and lymphomas. Targeting Myc has not been successful and is still an unmet clinical need for cancer patients.
Askgene Pharma Inc. has received FDA clearance of its IND application to start a phase I study of ASKG-915, a novel and proprietary anti-PD-1/IL-15 prodrug fusion molecule for the treatment of cancer.
Janssen Pharmaceutica NV and Johnson & Johnson (China) Investment Ltd. have identified substituted phenyl-1H-pyrrolo [2, 3-c] pyridine derivatives acting as menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer.
Impact Therapeutics (Shanghai) Inc. has synthesized nitrogen-containing fused heteroaromatic bicyclic compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Researchers from Nanjing University and China Pharmaceutical University have reported the discovery and preclinical evaluation of a novel KRAS(G12C) inhibitor.
Transcode Therapeutics Inc. has received clearance from the FDA to proceed with a first-in-human phase 0 trial of TTX-MC138 in cancer patients with advanced solid tumors. A single dose of radiolabeled TTX-MC138 will be followed by noninvasive PET-MRI to quantify the amount of radiolabeled TTX-MC138 delivered to metastatic lesions.
Simcere Pharmaceutical Group Ltd. has received IND approval from China's National Medical Products Administration (NMPA) for two immuno-oncology bispecific antibodies, SIM-0348 and SIM-0237.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. researchers have developed prodrugs acting as apoptosis regulator Bcl-2 inhibitors reported to be useful for the treatment of cancer, particularly chronic myeloid leukemia.
Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors, reported to be potentially useful for the treatment of cancer, have been detailed in a patent from Ennovabio (Zhejiang) Pharmaceuticals Co. Ltd. and Shanghai Ennova Biopharmaceutical Co. Ltd.
Researchers from Southeast University and Huanghuai University have reported the discovery of novel cyclin-dependent kinase 9 (CDK9) inhibitors as potential anticancer agents.
RSS
